BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24269836)

  • 1. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
    Dekker FJ; van den Bosch T; Martin NI
    Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
    Spange S; Wagner T; Heinzel T; Krämer OH
    Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach.
    Mroz RM; Noparlik J; Chyczewska E; Braszko JJ; Holownia A
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):453-60. PubMed ID: 18204158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
    Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.
    Leus NG; Zwinderman MR; Dekker FJ
    Curr Opin Chem Biol; 2016 Aug; 33():160-8. PubMed ID: 27371876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
    Simon RP; Robaa D; Alhalabi Z; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1249-70. PubMed ID: 26701186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.
    Cantley MD; Haynes DR
    Inflammopharmacology; 2013 Aug; 21(4):301-7. PubMed ID: 23341163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code.
    Calao M; Burny A; Quivy V; Dekoninck A; Van Lint C
    Trends Biochem Sci; 2008 Jul; 33(7):339-49. PubMed ID: 18585916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy.
    Stratton MS; McKinsey TA
    Biochem Cell Biol; 2015 Apr; 93(2):149-57. PubMed ID: 25707943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HAT/HDAC interplay: multilevel control of STAT signaling.
    Icardi L; De Bosscher K; Tavernier J
    Cytokine Growth Factor Rev; 2012 Dec; 23(6):283-91. PubMed ID: 22989617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
    van den Bosch T; Boichenko A; Leus NGJ; Ourailidou ME; Wapenaar H; Rotili D; Mai A; Imhof A; Bischoff R; Haisma HJ; Dekker FJ
    Biochem Pharmacol; 2016 Feb; 102():130-140. PubMed ID: 26718586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of protein acetylation in inflammatory lung diseases.
    Ito K; Charron CE; Adcock IM
    Pharmacol Ther; 2007 Nov; 116(2):249-65. PubMed ID: 17720252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of histone acetyltransferases and histone deacetylases in adipocyte differentiation and adipogenesis.
    Zhou Y; Peng J; Jiang S
    Eur J Cell Biol; 2014 Apr; 93(4):170-7. PubMed ID: 24810880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
    Edwards AJ; Pender SL
    Biochem Soc Trans; 2011 Aug; 39(4):1092-5. PubMed ID: 21787354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.